Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment

Table 2

The features of reports associated with Anastrozole from the 2013 Q1 to 2022 Q4.

	Anastrozole
	Counts	Percentages (%)
Number of events	3917
Gender
Male	160	4.08
Female	3366	85.93
Unknown	391	9.98
Age
<20	40	1.02
20–29	10	0.26
30–39	52	1.33
40–49	155	3.96
50–59	476	12.15
60–69	752	19.20
70–79	539	13.76
>80	238	6.08
Unknown	1655	42.25
Reported countries (the top ranked)
US (United States)	1647	42.05
UK (United Kingdom)	365	9.32
CA (Canada)	315	8.04
JP (Japan)	276	7.05
DE (Germany)	242	6.18
Serious outcomes
Hospitalization	636	16.24
Death	222	5.67
Disability	136	3.47
Life-threatening	112	2.86